Nektar Therapeutics (NKTR) Capital Expenditures (QoQ) (2010 - 2026)
Powered by 
Analysis
Nektar Therapeutics (NKTR) Capital Expenditures (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Nektar Therapeutics | 2.45 Bn | 1.77 Bn | 3.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 422.22% |
| Mar 31, 2026 | 0.00% |
| Dec 31, 2025 | -84.21% |
| Sep 30, 2025 | 208.11% |
| Jun 30, 2025 | 1,750.00% |
| Mar 31, 2025 | -99.56% |
| Dec 31, 2024 | -31.08% |
| Sep 30, 2024 | 258.06% |
| Jun 30, 2024 | 18.47% |
| Mar 31, 2024 | -33.76% |
| Dec 31, 2023 | 618.18% |
| Sep 30, 2023 | -79.63% |
| Jun 30, 2023 | -62.59% |
| Mar 31, 2023 | -15.43% |
| Dec 31, 2022 | 182.87% |
| Sep 30, 2022 | -76.79% |
| Jun 30, 2022 | -81.44% |
| Mar 31, 2022 | -28.71% |
| Dec 31, 2021 | 100.82% |
| Sep 30, 2021 | -10.52% |